论文部分内容阅读
目的探讨107例经EGFR-TKIs一线治疗的晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者血肿瘤标记物水平与疗效的关系。方法 2008-2011年共107例NSCLC患者接受EGFR-TKIs的一线治疗,并在治疗前进行了血肿瘤标记物的检测。根据检查结果分为高表达组和低表达组,观察两组近期疗效,并进行相关性分析。结果 CEA≥5 ng/ml的患者EGFR-TKIs治疗有效率为23.4%(15/64),疾病控制率为70.3%(45/64),CEA<5 ng/ml的患者有效率为15.0%(6/40),疾病控制率为47.5%(19/40),疗效差异有统计学意义(P<0.05);CEA高表达患者PFS与CEA低表达患者相比差异无统计学意义(5.7个月vs 7.3个月,P=0.220)。其余的血肿瘤指标包括CA125、NSE、SCC及CYFRA21-1高表达组与低表达组之间DCR、ORR及PFS差异无统计学意义(P>0.05)。进一步分析了CEA高表达组和低表达组患者的一般临床特征,结果显示两组患者差异无统计学意义(P>0.05)。结论血清CEA水平可作为预测EGFR-TKIs治疗疗效的指标,与PFS关系并不确定。
Objective To investigate the relationship between the level of hematologic markers and the therapeutic effect in 107 patients with advanced non-small cell lung cancer (NSCLC) treated with EGFR-TKIs. Methods A total of 107 NSCLC patients undergoing first-line treatment with EGFR-TKIs between 2008 and 2011 were tested for hematological tumor markers prior to treatment. According to the test results were divided into high expression group and low expression group, to observe the two groups of short-term efficacy, and correlation analysis. Results The effective rate of EGFR-TKIs treatment was 23.4% (15/64) in patients with CEA≥5 ng / ml, and the rate of disease control was 70.3% (45/64). The effective rate of patients with CEA <5 ng / ml was 15.0% (P <0.05). There was no significant difference between PFS and low expression of CEA in patients with high CEA expression (5.7 months vs 7.3 months, P = 0.220). There were no significant differences in DCR, ORR and PFS between the rest of the hematologic malignancies including CA125, NSE, SCC and CYFRA21-1 high expression group and low expression group (P> 0.05). Further analysis of the CEA high expression group and low expression group of patients with general clinical features, the results showed no significant difference between the two groups of patients (P> 0.05). Conclusions Serum CEA level may be used as an index for predicting the therapeutic effect of EGFR-TKIs, but its relationship with PFS is uncertain.